|
Adjuvant treatment
|
Recommendation
|
|---|
|
Modality
|
Expertise
|
Recorded
|
Recommended
|
Not Recommended
|
For discussion
|
|---|
| | |
N
|
(%)
|
N
|
(%)
|
N
|
(%)
|
N
|
(%)
|
|---|
|
Chemotherapy
|
MDT
|
975
|
(92)
|
342
|
(35)
|
393
|
(40)
|
240
|
(25)
|
|
ESMO
|
1065
|
(100)
|
321
|
(30)
|
701
|
(66)
|
43
|
(4)
|
|
NCCN
|
1065
|
(100)
|
489
|
(46)
|
80
|
(8)
|
496
|
(47)
|
|
Endocrine therapy
|
MDT
|
1002
|
(94)
|
794
|
(79)
|
86
|
(9)
|
122
|
(2)
|
|
ESMO
|
1065
|
(100)
|
927
|
(87)
|
138
|
(13)
|
0
|
(0)
|
|
NCCN
|
1065
|
(100)
|
874
|
(82)
|
143
|
(13)
|
48
|
(5)
|
|
Trastuzumab
|
MDT
|
456
|
(43)
|
86
|
(19)
|
363
|
(80)
|
7
|
(2)
|
|
ESMO
|
1065
|
(100)
|
142
|
(13)
|
923
|
(87)
|
0
|
(0)
|
|
NCCN
|
1065
|
(100)
|
125
|
(12)
|
929
|
(87)
|
11
|
(1)
|
- MDT multidisciplinary conference, ESMO European society for medical oncology, NCCN national comprehensive cancer network
